Your browser doesn't support javascript.
loading
Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
de Vries Schultink, Aurelia H M; Huitema, Alwin D R; Beijnen, Jos H.
Affiliation
  • de Vries Schultink AHM; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Electronic address: ah.d.vriesschultink@nki.nl.
  • Huitema ADR; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
  • Beijnen JH; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; Science Faculty, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.
Breast ; 42: 38-40, 2018 Dec.
Article in En | MEDLINE | ID: mdl-30153552
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Antineoplastic Agents, Hormonal / Precision Medicine Language: En Journal: Breast Year: 2018 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Antineoplastic Agents, Hormonal / Precision Medicine Language: En Journal: Breast Year: 2018 Type: Article